Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Guggenhime also recently made the following trade(s):

• On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $88.78, for a total value of $710,240.00.

Vaxcyte Stock Down 0.4 %

PCVX stock opened at $89.64 on Friday. The company’s 50-day moving average price is $87.24 and its two-hundred day moving average price is $93.85. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06. The firm has a market cap of $11.17 billion, a P/E ratio of -19.49 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the company earned ($0.91) EPS. Equities analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Institutional Trading of Vaxcyte

Several large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vaxcyte by 68.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after acquiring an additional 8,685 shares during the last quarter. Natixis Advisors LLC lifted its stake in Vaxcyte by 61.1% in the 3rd quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after purchasing an additional 8,606 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Vaxcyte in the second quarter valued at approximately $1,053,000. Lisanti Capital Growth LLC grew its stake in shares of Vaxcyte by 68.1% during the third quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock worth $3,715,000 after buying an additional 13,175 shares during the last quarter. Finally, Diversified Trust Co acquired a new position in shares of Vaxcyte during the fourth quarter worth $1,433,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the company. The Goldman Sachs Group began coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.